EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors

Chenyu Zhang, Charles Chien, Eglė Jurgaitytė, Koharu Sakiyama, Alissa Bockman, Yeara Jo, Seungwon Lee, Stephanie Silveria, Elizabeth Andrews, Abigail Mende, Lily Zhang, K. Christopher Garcia, Allon Wagner, Michel DuPage, David Raulet

Science Immunology · 2026-04-10 · 11 (118)

DOI: 10.1126/sciimmunol.adx4411 ↗
AbstractBibliografische Angaben

Abstract

Cancer cells frequently lose major histocompatibility complex class I (MHC I) to evade CD8 T cell recognition. Natural killer (NK) cells are poised to target MHC I–deficient cancer cells, but MHC I loss alone is often insufficient to unleash fully effective NK cell responses. Here, we show that selective intratumoral (IT) ablation of regulatory T cells (T reg cells) elicited potent antitumor NK cell responses that controlled MHC I–deficient and even MHC I + cancers that expressed NKG2D ligands. T reg cells controlled the activation, maturation, and antitumor cytotoxic activity of NK cells within the tumor microenvironment. Mechanistically, depletion of IT-T reg cells relieved the inhibition of cDC2-dependent induction of IL-2 production by conventional CD4 T cells that was necessary for NK cell activation. Systemically administered antibodies that selectively depleted IT-T reg cells similarly empowered NK cell–dependent tumor control. These findings expand the breadth of T reg cell–mediated cancer immunosuppression to encompass antitumor NK cells and suggest that therapeutic targeting of T reg cells in tumors can control CD8 T cell–resistant cancers.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →